Key Points
- Insider sales: VP Harry Shuman sold 1,700 shares on Nov. 26 at an average of $96.10 ($163,370) after selling 8,300 shares on Nov. 25 at $95.92 ($796,136), leaving him with 11,002 shares and representing a 13.38% reduction in his position.
- Merus is a clinical-stage immuno-oncology company (lead candidate Zenocutuzumab in Phase 2) with a market cap of about $7.34 billion; analysts have a consensus rating of Hold and a $93.56 target, and institutional investors own roughly 96% of the stock.
Merus N.V. (NASDAQ:MRUS - Get Free Report) VP Harry Shuman sold 1,700 shares of the firm's stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $96.10, for a total value of $163,370.00. Following the completion of the sale, the vice president directly owned 11,002 shares in the company, valued at approximately $1,057,292.20. This represents a 13.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
Harry Shuman also recently made the following trade(s):
- On Tuesday, November 25th, Harry Shuman sold 8,300 shares of Merus stock. The stock was sold at an average price of $95.92, for a total value of $796,136.00.
Merus Stock Down 0.0%
Shares of MRUS stock opened at $96.77 on Thursday. The business has a fifty day simple moving average of $95.31 and a 200 day simple moving average of $73.89. The company has a market cap of $7.34 billion, a P/E ratio of -18.26 and a beta of 1.06. Merus N.V. has a twelve month low of $33.19 and a twelve month high of $96.83.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in MRUS. CWM LLC lifted its position in shares of Merus by 299.0% in the 2nd quarter. CWM LLC now owns 802 shares of the biotechnology company's stock worth $42,000 after purchasing an additional 601 shares during the period. Quarry LP bought a new stake in Merus during the third quarter valued at $42,000. Farther Finance Advisors LLC grew its holdings in Merus by 10,400.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 525 shares of the biotechnology company's stock worth $49,000 after acquiring an additional 520 shares during the period. Longfellow Investment Management Co. LLC bought a new position in shares of Merus in the 3rd quarter worth about $75,000. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of Merus by 955.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,794 shares of the biotechnology company's stock valued at $76,000 after purchasing an additional 1,624 shares in the last quarter. Institutional investors own 96.14% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms recently issued reports on MRUS. Barclays reiterated an "equal weight" rating and set a $97.00 price objective (down from $112.00) on shares of Merus in a research report on Tuesday, September 30th. Alliance Global Partners initiated coverage on Merus in a report on Monday, August 25th. They set a "buy" rating and a $90.00 price objective on the stock. Wells Fargo & Company restated an "equal weight" rating and set a $97.00 price objective (up previously from $95.00) on shares of Merus in a research report on Monday, September 29th. Industrial Alliance Securities set a $90.00 price target on Merus in a research note on Monday, August 25th. Finally, Leerink Partners reaffirmed a "market perform" rating and issued a $97.00 price objective (up previously from $95.00) on shares of Merus in a research note on Monday, October 6th. Three analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Merus currently has a consensus rating of "Hold" and a consensus target price of $93.56.
Read Our Latest Report on Merus
About Merus
(
Get Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
